<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166792">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926380</url>
  </required_header>
  <id_info>
    <org_study_id>20080723</org_study_id>
    <secondary_id>2009P000525</secondary_id>
    <nct_id>NCT00926380</nct_id>
  </id_info>
  <brief_title>Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis</brief_title>
  <acronym>DATA</acronym>
  <official_title>The Denosumab And Teriparatide Administration Study (DATA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis
      therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will
      increase bone mineral density more than either one alone in postmenopausal osteoporotic
      women.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density by Dual X-ray Absorptiometry (DXA)</measure>
    <time_frame>06/2009-02/2015</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>denosumab ONLY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>teriparatide (Forteo®) ONLY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>denosumab and teriparatide (Forteo®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>denosumab: 60 mg SC every 6 months</description>
    <arm_group_label>denosumab ONLY</arm_group_label>
    <arm_group_label>denosumab and teriparatide (Forteo®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>teriparatide: 20 mcg SC QD</description>
    <arm_group_label>teriparatide (Forteo®) ONLY</arm_group_label>
    <arm_group_label>denosumab and teriparatide (Forteo®)</arm_group_label>
    <other_name>Forteo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Must satisfy A and B and C and D below:

          -  (A) Women aged &gt; 55

          -  (B) Postmenopausal

          -  (C) Osteoporotic with high risk of fracture

        Exclusion Criteria:

          -  Confirmed serum alkaline phosphatase above upper normal limit with no explanation

          -  Liver disease (AST or ALT &gt; 2 x upper normal limit).

          -  Renal disease (serum creatinine &gt; 2.0 mg/dl).

          -  Hypercalcemia (Ca &gt;10.5 mg/dL)

          -  Elevated blood PTH (intact PTH &gt; 65 pg/ml)

          -  Serum 25-OH vitamin D &lt; 20 ng/ml

          -  HCT &lt; 32%.

          -  History of malignancy (except basal cell carcinoma) or radiation therapy.

          -  Significant cardiopulmonary disease including unstable coronary artery disease, stage
             D ACC/AHA heart failure or any other condition that the investigator deems may
             preclude the subject from participating safely or completing the protocol procedures.

          -  Major psychiatric disease that in the opinion of the investigator would preclude the
             subject from providing adequate informed consent or completing the protocol
             procedures.

          -  Excessive alcohol use or substance abuse that in the opinion of the investigator
             would preclude the subject from providing adequate informed consent or completing the
             protocol procedures.

          -  Known congenital or acquired bone disease other than osteoporosis (including
             osteomalacia, hyperparathyroidism, Paget's disease)

          -  Current use or use in the past 6 months of oral bisphosphonate

          -  Current use or use within the past 3 months of estrogens, selective estrogen receptor
             modulators, or calcitonin.

          -  Use of oral or parenteral glucocorticoids for more than 14 days within the past 6
             months.

          -  Any current or previous use of strontium or any parenteral bisphosphonate.

          -  Known sensitivity to mammalian cell-derived drug products.

          -  Known sensitivity to teriparatide or any of its excipients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Z Leder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M Neer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41.</citation>
    <PMID>11346808</PMID>
  </reference>
  <reference>
    <citation>Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators.. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15. Epub 2003 Sep 20.</citation>
    <PMID>14500804</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-26. Epub 2003 Sep 20.</citation>
    <PMID>14500805</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001 May;16(5):925-31.</citation>
    <PMID>11341338</PMID>
  </reference>
  <reference>
    <citation>Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001 Oct;142(10):4295-304.</citation>
    <PMID>11564687</PMID>
  </reference>
  <reference>
    <citation>Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998 Apr 17;93(2):165-76.</citation>
    <PMID>9568710</PMID>
  </reference>
  <reference>
    <citation>Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602.</citation>
    <PMID>9520411</PMID>
  </reference>
  <reference>
    <citation>Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008 Jun;93(6):2149-57. doi: 10.1210/jc.2007-2814. Epub 2008 Apr 1.</citation>
    <PMID>18381571</PMID>
  </reference>
  <reference>
    <citation>Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J; Amg Bone Loss Study Group.. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-9. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26.</citation>
    <PMID>18539106</PMID>
  </reference>
  <reference>
    <citation>Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab. 2007 Mar;92(3):942-7. Epub 2006 Dec 12.</citation>
    <PMID>17164314</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>June 19, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>teriparatide</keyword>
  <keyword>Forteo®</keyword>
  <keyword>DXA</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>pQCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
